Ftse Mib
33.707,21
-0,38%
DAX
18.177,62
-0,90%
S&P 500
5.469,30
0,39%
NASDAQ
17.717,65
1,26%
Bitcoin
62.106,78
0,49%
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Inotek Pharmaceuticals Corp. (delisted) (ITEK) Inotek Pharmaceuticals Corp. (delisted) (ITEK) Notizie

ITEK

INOTEK PHARMACEUTICALS CORP (ITEK)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ITEK
DataOraFonteTitoloSimboloCompagnia
14/02/201823:51Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
31/01/201820:31Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
25/01/201823:14Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
25/01/201822:16Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
19/01/201823:03Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
19/01/201819:52Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
16/01/201822:09Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
11/01/201822:32Edgar (US Regulatory)Amended Securities Registration (section 12(b)) (8-a12b/a)NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
22/12/201722:52Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
04/12/201722:13Edgar (US Regulatory)Proxy Statement - Merger or Acquistion (definitive) (defm14a)NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
20/11/201723:02Edgar (US Regulatory)Proxy Soliciting Materials (revised) (prer14a)NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
08/11/201714:03Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
12/10/201723:20Business WireInotek Pharmaceuticals Announces Filing of Preliminary Proxy Statement for Proposed Merger with Clinical-stage Gene Therapy C...NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
12/10/201723:08Edgar (US Regulatory)Proxy Statement - Merger or Acquistion (preliminary) (prem14a)NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
18/09/201722:49Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
13/09/201700:06Business WireINSERTING & REPLACING Inotek Pharmaceuticals Announces Merger Agreement with Rocket Pharmaceuticals to Advance Pipeline of Fi...NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
12/09/201722:15Business WireInotek Pharmaceuticals Announces Merger Agreement with Rocket Pharmaceuticals to Advance Pipeline of First-in-Class Gene Ther...NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
03/08/201722:01Business WireInotek Pharmaceuticals Corporation Reports Second Quarter 2017 Financial Results and Operational HighlightsNASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
07/07/201722:01Business WireInotek Pharmaceuticals Announces Top-line Results of Phase 2 Fixed-dose Combination Trial of Trabodenoson & Provides Corporat...NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
10/05/201713:00Business WireInotek Pharmaceuticals Corporation Reports First Quarter 2017 Financial Results and Operational HighlightsNASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
08/05/201722:05Business WireInotek Pharmaceuticals Presents Preclinical Data on Trabodenoson at the Association for Research in Vision & Ophthalmology (A...NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
26/04/201722:48Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
11/04/201713:00Business WireInotek Completes Patient Recruitment in Phase 2 Trial of a Fixed-dose Combination (FDC) of Trabodenoson and LatanoprostNASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
23/03/201712:47Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
16/03/201712:43Edgar (US Regulatory)Annual Report (10-k)NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
16/03/201712:00Business WireInotek Pharmaceuticals Corporation Reports Fiscal Year 2016 Financial Results and Operational HighlightsNASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
27/02/201713:00Business WireInotek Pharmaceuticals Announces Participation at Upcoming Investor ConferencesNASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
25/02/201702:22PR Newswire (US)URGENT: Monteverde & Associates PC Invites Inotek Pharmaceuticals Corporation Shareholders with Losses To Contact The Firm Im...NASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
24/02/201713:00Business WireInotek Pharmaceuticals Announces Poster Presentations on Trabodenoson at the American Glaucoma Society 2017 Annual MeetingNASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
10/02/201715:00Business WireInotek Pharmaceuticals to Present at the BIO CEO and Investor ConferenceNASDAQ:ITEKInotek Pharmaceuticals Corp. (delisted)
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ITEK

La tua Cronologia

COIN
DPCTBTC
Dipitto
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network